The stock price of Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has dropped by -0.36 compared to previous close of 1.39. Despite this, the company has seen a fall of -0.36% in its stock price over the last five trading days. businesswire.com reported 2024-08-19 that RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company’s development program for ZTALMY® (ganaxolone) oral suspension CV in.
Is It Worth Investing in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) Right Now?
Moreover, the 36-month beta value for MRNS is 1.12. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MRNS is 47.97M and currently, short sellers hold a 5.71% of that float. On September 12, 2024, MRNS’s average trading volume was 687.56K shares.
MRNS’s Market Performance
The stock of Marinus Pharmaceuticals Inc (MRNS) has seen a -0.36% decrease in the past week, with a 17.37% rise in the past month, and a -7.05% fall in the past quarter. The volatility ratio for the week is 4.23%, and the volatility levels for the past 30 days are at 6.56% for MRNS. The simple moving average for the past 20 days is 1.88% for MRNS’s stock, with a -73.20% simple moving average for the past 200 days.
Analysts’ Opinion of MRNS
Robert W. Baird, on the other hand, stated in their research note that they expect to see MRNS reach a price target of $2, previously predicting the price at $20. The rating they have provided for MRNS stocks is “Neutral” according to the report published on April 16th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to MRNS, setting the target price at $3 in the report published on April 15th of the current year.
MRNS Trading at 3.85% from the 50-Day Moving Average
After a stumble in the market that brought MRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.70% of loss for the given period.
Volatility was left at 6.56%, however, over the last 30 days, the volatility rate increased by 4.23%, as shares surge +26.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.23% upper at present.
During the last 5 trading sessions, MRNS rose by +0.36%, which changed the moving average for the period of 200-days by -78.41% in comparison to the 20-day moving average, which settled at $1.3742. In addition, Marinus Pharmaceuticals Inc saw -87.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNS starting from Pfanstiel Steven, who sale 4,657 shares at the price of $1.13 back on Aug 05 ’24. After this action, Pfanstiel Steven now owns 79,773 shares of Marinus Pharmaceuticals Inc, valued at $5,262 using the latest closing price.
Shafer Christina, the CHIEF COMMERCIAL OFFICER of Marinus Pharmaceuticals Inc, sale 3,820 shares at $1.14 during a trade that took place back on Aug 05 ’24, which means that Shafer Christina is holding 67,406 shares at $4,355 based on the most recent closing price.
Stock Fundamentals for MRNS
Current profitability levels for the company are sitting at:
- -4.4 for the present operating margin
- 0.89 for the gross margin
The net margin for Marinus Pharmaceuticals Inc stands at -4.93. The total capital return value is set at -2.6. Equity return is now at value -2986.55, with -103.54 for asset returns.
Based on Marinus Pharmaceuticals Inc (MRNS), the company’s capital structure generated 1.98 points at debt to capital in total, while cash flow to debt ratio is standing at -1.26. The debt to equity ratio resting at -2.02. The interest coverage ratio of the stock is -14.77.
Currently, EBITDA for the company is -130.93 million with net debt to EBITDA at -0.24. When we switch over and look at the enterprise to sales, we see a ratio of 3.55. The receivables turnover for the company is 8.81for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.28.
Conclusion
To wrap up, the performance of Marinus Pharmaceuticals Inc (MRNS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
